Prevention of restenosis after coronary intervention is a major clinical challenge, which highlights the need of new therapeutic options. Vascular injury may involve inflammatory responses that accelerate the recruitment and activation of monocytes through the activation of chemotactic factors, including monocyte chemoattractant protein-1 (MCP-1). However, there is no definitive evidence supporting the role of MCP-1 in restenosis. We recently devised a new strategy for anti-MCP-1 gene therapy by transfecting an N-terminal deletion mutant of the MCP-1 gene into skeletal muscles. We demonstrate here that this strategy suppressed monocyte infiltration/activation in the injured site and markedly inhibited restenotic changes (neointimal hyperplasia) after balloon injury of the carotid artery in rats and monkeys. This strategy also suppressed the local production of MCP-1 and inflammatory cytokines. Therefore, monocyte infiltration and activation mediated by MCP-1 are essential in the development of restenotic changes after balloon injury. This strategy may be a useful form of gene therapy against human restenosis.
recruitment and activation of monocytes through the activation of chemotactic factors, including monocyte chemoattractant protein-1 (MCP-1) (4-6). MCP-1 is a potent chemotactic factor for monocytes (7, 8) . Prior studies have indicated that MCP-1 expression is increased in atherosclerotic lesions (9, 10) and balloon injured arteries (11) and that eliminating MCP-1 gene or blockade of MCP-1 signals decreases atherogenesis in hypercholesterolemic mice (12) (13) (14) . We have shown that MCP-1 plays an important role in coronary arteriosclerosis in a rat model of nitric oxide synthesis inhibition (15) (16) (17) (18) . However, no prior study addressed the definite role of monocytes or MCP-1-mediated signals in the development of neointimal hyperplasia after balloon injury.
Recently, we devised a new strategy for anti-MCP-1 gene therapy by transfecting mutant MCP-1 genes into skeletal muscle (14) (15) (16) (17) (18) (19) . This mutant MCP-1 lacks the N-terminal amino acid 2-8, called 7ND, and has been shown to work as a dominant-negative inhibitor of MCP-1. This method (intramuscular transfection of the gene) is useful, because direct gene transfer into the injured arterial wall is not necessary and definitive roles of MCP-1 can be investigated under pathophysiologic conditions in vivo. In this study, we used our anti-MCP-1 gene therapy to test the hypothesis that MCP-1-mediated inflammation is essential in the development of restenotic changes after balloon injury.
MATERIALS AND METHODS

Plasmid expression vectors
Human 7ND cDNA was constructed by recombinant polymerase chain reaction, using a wild-type human MCP-1 cDNA (Dr. T. Yoshimura, National Cancer Institute) as a template, and inserted into the BamH1 (5') and Not1 (3') sites of the pcDNA3 (Invitrogen, Carlsbad, CA) expression vector plasmid (19) .
An animal model of balloon injury and gene transfer
These experiments were reviewed and approved by the Committee on Ethics on Animal Experiments, Kyushu University Faculty of Medicine, and according to the Guidelines of the American Physiologic Society. A part of this study was performed at the Kyushu University Station for Collaborative Research and the Morphology Core.
We anesthetized twenty-week-old male Wistar-Kyoto rats by i.p. injection of pentobarbital. Their right common carotid arteries were injured by three times passages of an inflated 2F Fogarty balloon catheter. We took care to keep constant the diameter of the balloon and the resistance during withdrawal. Rats with the sham operation were treated in the same manner, without balloon injury. After the operation, all rats were allowed to recover from the surgery. Five-year-old male adult cynomolgus monkeys weighing 4-5 kg were purchased from Japan Charles-River, Shizuoka, and were fed a commercial laboratory diet. Monkeys were anesthetized with ketamine hydrochloride (10 mg/kg IM) and sodium pentobarbital (30 mg/kg IV to effect), and balloon injury of the right carotid arteries was performed by the use of 4F Fogarty balloon catheter.
Three days before the balloon injury, rats were randomly divided into two groups: The empty plasmid group was injected with the empty plasmid gene and the 7ND group was injected with the 7ND gene by using a 27-gauge needle in the femoral muscle (300 µg/150 µl phosphate-buffered saline [PBS] in rats). To enhance transgene expression, all rats received electroporation at the injected site. Immediately after the empty plasmid or 7ND gene was injected into the femoral muscle, a pair of electrode needles (Tokiwa Science) spaced 5 mm apart were inserted into the muscle on either side of the injected sites. Six 100-V square wave pulses (spaced 150 msec apart) were applied, followed by six pulses in the opposite polarity for 50 ms, using an electric pulse generator CUY201 (BTX). Then, the wound was closed. No inflammation was observed at the injection sites. To assess transgene expression, the luciferase activity of femoral muscle injected with PBS or pcDNA3 plasmid with luciferase gene was determined. Luciferase activity was measured using a liquid scintillation counter (Lumat LB9507) and expressed as relative light units (RLUs) per milligram of total protein.
Monkeys were also injected and pretreated with empty plasmid or 7ND plasmid (2000 µg/500 µl PBS) in their femoral muscles immediately after balloon injury. To enhance transgene expression, all monkeys were pretreated with an intramuscular injection of bupivacine (0.25 mg/kg) at the injected site 3 days before plasmid injection.
To determine biological effects of 7ND transfection, an in vivo matrigel plug assay was performed in rats and monkeys. In brief, matrigel (200 µL) alone or mixed with human MCP-1 (R & D) at a concentration of 1 ng/µL was injected s.c. into the flank of rats and monkeys. On days 7 and 14, animals were anesthetized, and plugs were removed and fixed, paraffin-embedded, and stained with hematoxylin eosin.
At various time points, rats were killed with a lethal dose of anesthesia. Monkeys were killed with a lethal dose of anesthesia 28 days after balloon injury. After administration of heparin, venous blood was collected and prepared as plasma for later analysis.
Histopathology and immunohistochemistry
For morphometrical analysis, the common carotid arteries were fixed for 24 h with 6% paraformaldehyde. Tissue was dehydrated, embedded in paraffin, and cut into slices 5 µm thick.
Sections were either stained with elastic van Gieson and hematoxylin eosin stain or subjected to immunostaining, using antibodies against macrophage/monocyte (ED1, Serotec, Oxford, UK), proliferating cell nuclear antigen (PCNA) (Dako, Glostrup, Denmark), α-smooth muscle actin antibody (Dako), T lymphocyte antibody (CD3, Dako), MCP-1 antibody, CCR2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), von Wilbrand factor (Dako) or no-immune mouse IgG (Dako). The slides were washed and incubated with biotinylated, affinity-purified goat anti-rabbit IgG. Following avidin-biotin amplification, the slides were incubated with diaminobenzidine and counterstained with hematoxylin. In each tissue (five sections per artery) stained with ED1, CD3, and PCNA, the sum of the total immunopositive cells and the number of the total cells in each sections were counted. Then the percentage of immunopositive cells per total cells in each section was calculated, and the average of the five sections was reported for each animal.
To evaluate the thickening of the neointima, the areas encroached by the external elastic lamina (EEL area), the internal elastic lamina (IEL area), and the lumen area were measured. Other areas were calculated as follows: medial area = EEL area -IEL area; neoimtimal area = IEL area -lumen area; neointima-to-media ratio (I/M) = neointimal area/medial area.
ELISA
Common carotid arteries were homogenized, and tissue concentrations of rat MCP-1, CINC-1 (the rat homologue of IL [IL]-8), IL-1β, IL-6, tumor necrosis factor (TNF)-α, IL-2, interferon-γ, IL-4, and IL-10 were measured by the use of commercially available ELISA kits (Biosource, Camarillo, CA).
To measure 7ND released by the transfected skeletal muscle, plasma concentrations of 7ND were measured by the use of human MCP-1 ELISA kit (Biosource). Because this human MCP-1 ELISA kit does not react with the rat MCP-1, it is reasonable to consider that plasma 7ND concentrations can be measured with this kit.
Real-time reverse quantitative transcription PCR
In a separate set of animals, total RNA from carotid arteries was reverse transcribed, and the resultant cDNA was amplified by TaqMan real-time reverse transcription PCR on the ABI Prism 7000 Sequence Detection System (20) . Controls consisting of dH2O were negative for target and the housekeeper, GAPDH. Real-time reverse transcription PCR for MCP-1 was carried out with the following primers: sense primer 5'-CCTCCACCACTATGCAGGTCTC-3', antisense primer 5'-GCACGTGGATGCTACAGGC-3' and probe oligonucleotides 5'-TCACGCTTCTGGGCCTGTTGTTCA-3'. CCR2 was amplified in the same way with the following primers: sense primer 5'-ACCTGTTCAACCTGGCCATCT-3', antisense primer 5'-AGACCCACTCATTTGCAGCAT-3' and probe oligonucleotides 5'-ACCTGCTCTTCCTGCTCACACTCCCA-3'. GAPDH probe was obtained from Applied Biosystems (Foster City, CA).
Statistical analysis
Data are expressed as mean ±SE. Statistical analysis of differences was compared by ANOVA and Bonferroni's multiple comparison tests. A level of P<0.05 is considered statistically significant.
RESULTS
MCP-1 and CCR2 Expression
The MCP-1 and CCR2 mRNA levels were undetectably low in noninjured left carotid artery (Fig.  1A) . Both MCP-1 and CCR2 mRNA levels significantly increased as early as day 3 but declined with time; at all time points, however, gene expression of MCP-1 and CCR2 in the injured artery was significantly higher on days 3, 7, and 28 than that in the noninjured control artery.
Immunostaining showed that MCP-1 was undetectable in the noninjured control artery, whereas intense MCP-1 immunoreactivity was evident mainly in the neointima and media 7 days after balloon injury and in the endothelial layer and neointima 28 days after balloon injury (Fig. 1B) . Because cells in the neointima consist exclusively of vascular smooth muscle cells in the rat model, it is highly likely that MCP-1-expressing cells are smooth muscle cells and endothelial cells. The cell type expressing CCR2 was determined by fluorescence immunohistochemistry (Fig. 2B) . Immunoreactive CCR2 was present exclusively in the monocytes/macrophages that had infiltrated into the intima and media of injured arteries. No such CCR2-positive cells were noted in the control noninjured artery (data not shown). CCR2 immunoreactivity was also observed in the endothelial cell layer, the degrees of which did not differ among the three groups (data not shown).
Effects of 7ND gene transfer on neointimal hyperplasia
Rats were killed at 3, 7, 14, and 28 days after balloon injury. Significant fibromuscular neointimal hyperplasia was observed 28 days after balloon injury, as observed in previous studies by others. (21) We detected ED1-positive monocytes, CD3-positive T lymphocytes, and PCNA-positive cells in the intima and media (Fig. 2A) . These inflammatory and proliferative changes persisted mainly in the neointima at 28 days. Endothelial cells, monitored by von Wilbrand factor immunoreactivity, were observed equally in animals transfected with empty plasmid and those with 7ND gene 7, 14, and 28 days after balloon injury (Fig. 2C) .
In rats, both inflammation (ED1-positive cells) and proliferation (the PCNA index) were markedly less in 7ND-transfected rats than in empty plasmid-transfected rats at 7 and 28 days (Fig. 3A) . In contrast, the number of CD3-positive cells did not differ between the two groups. 7ND gene transfer significantly reduced the neointimal hyperplasia (increases in neointimal area and intima/media ratio) 28 days after balloon injury (Fig. 3B ). 7ND gene transfer markedly reduced the increases in MCP-1 and CCR2 gene expression and in MCP-1 immunoreactivity (Fig. 1) . 7ND gene transfer markedly reduced the appearance of CCR2-positive cells. The CCR2 immunoreactivity was also observed in the endothelial cell layer, the degrees of which did not differ among the three groups. In monkeys, significant fibromuscular neointimal hyperplasia was noted 28 days after balloon injury, and 7ND gene transfer markedly reduced the neointimal formation (Fig. 4) .
Effects of 7ND gene transfer on tissue chemokine and cytokine concentrations
We also measured carotid artery tissue concentrations of various cytokines and chemokines 7 and 28 days after balloon injury (Table 1) . Tissue concentrations of MCP-1, but not CINC-1 (the rat homologue of IL-8), were higher in the empty plasmid group than in the normal control group. Other cytokines (TNFα, IL-1β, IL-6, IL2, IL-4, IL-10, and INFγ) also were higher in the empty plasmid group than in the normal control group. 7ND gene transfer partly but significantly reduced the increase in tissue MCP-1 concentrations. 7ND gene transfer did not affect the increase in IL-2, IL-4, IL-6, and INFγ, but it did partly reduce the increase in TNFα, IL-1β, and IL-10 levels.
Trangene expression and plasma concentrations of MCP-1 and 7ND
We measured MCP-1 and 7ND after 7ND transfection and balloon injury. Plasma MCP-1 concentrations did not change during the course of experiments, whereas 7ND was detected in plasma 3, 7, and 14 days after transfection (Table 2) . Compared with PBS-injected muscle (5.0 ± 1.0 × 10 1 RLU/mg protein), the luciferase activity of the muscles injected with luciferase gene plasmid on days 1, 3, 7, 14, and 28 was 2.6 ± 0.1 × 10 7 , 7.8 ± 0.5 × 10 7 , 9.8 ± 0.9 × 10 7 , 8.8 ± 0.6 × 10 7 , and 5.2 ± 0.2 × 10 3 RLU/mg protein (all P<0.01 vs. PBS), respectively.
In vivo matrigel plug assay
Histologic sections of the matrigel plugs showed significant monocyte recruitment induced by MCP-1 compared with matrigel alone in rats (Fig. 5 ) and monkeys (data not shown). 7ND gene transfer suppressed such effects induced by MCP-1 to a level similar to that observed in the control matrigel plugs lacking MCP-1 7 and 14 days after 7ND gene transfection (Fig. 5) . Such suppression was not noted 28 days after 7ND gene transfection or after injection of empty plasmid (data not shown).
DISCUSSION
Here, we demonstrate for the first time the definite role of inflammatory responses mediated by MCP-1 in the development of restenotic changes after balloon injury. Our data strongly suggest that the MCP-1-mediated vascular inflammatory response is strikingly important in neointimal formation after balloon injury.
Prior studies have shown that balloon injury to the arterial wall induced rapid and transient increases in mRNA and protein levels of MCP-1 (11). Interestingly, a rapid increase in plasma MCP-1 within the first day of coronary angioplasty is reported in patients (22) . Persistent increase in MCP-1 after angioplasty was shown to be statistically significant and an independent predictor of restenosis (22) . We show persistent increases in gene expression of MCP-1 and CCR2 as well as in protein production of MCP-1 after balloon injury in rats. 7ND gene transfer markedly attenuated early inflammatory and proliferative changes and later neointimal hyperplasia, indicating the definite role of MCP-1 in neointimal hyperplasia after balloon injury. Activated monocytes may serve as a source of growth factors and cytokines. Our data, therefore, indicate that locally produced MCP-1 not only induced the recruitment of monocytes but also activated lesional monocytes and vascular smooth muscle cells to produce the inflammatory cytokines, which might in turn cause neointimal hyperplasia. Thus, MCP-1-mediated inflammation in the arterial wall is likely to create the positive-feedback mechanism to enhance inflammation and proliferation of injured arterial wall (Fig. 5) . Although we did not determine the mechanism underlying the activation of the MCP-1 pathway after balloon injury, it is plausible to speculate that increased oxidative stress and redox-sensitive transcription factors such as nuclear factor-κB might have contributed to the increased MCP-1 expression as we had reported in a rat model of long-term inhibition of nitric oxide synthesis (15) (16) (17) (18) .
The outstanding effects (∼70% inhibition) of 7ND gene transfer in rats and monkeys imply that this gene-transfer strategy can be a novel therapy against human restenosis. Our finding in nonhuman primates seems meaningful, because many therapeutic strategies that have proven effective in reducing restenosis in nonprimate animal models have failed to demonstrate a substantial effect on human restenosis. This study is the first to demonstrate the suppression of neointimal hyperplasia after balloon injury in primates.
Furukawa et al. (23) reported that injection of polyclonal antibody against rat MCP-1 modestly reduced neointimal formation in a rat model of carotid artery balloon injury. In that study (23) , the mechanism by which the MCP-1 antibody attenuated neointimal formation remains unclear because the MCP-1 antibody neither reduced monocyte infiltration nor PCNA-positive cells in vivo. More recently, Horvath et al. (24) showed that injection of an antibody against murine CCR2 had no effect on neointimal hyperplasia after iliac arterial balloon injury in monkeys. The magnitudes of inflammatory response seem to be less in these two studies than those in this study. Note that failure of inhibiting neointimal hyperplasia by CCR2 antibody in the study of Horvath et al. (24) might have been due to the use of a murine antibody in monkeys.
In conclusion, inflammatory changes mediated by MCP-1 are essential in the development of restenotic changes (neointimal formation) after balloon injury. This study may support the hypothesis that 1) inflammation may be a central part of the pathogenesis of restenosis, and 2) this anti-MCP-1 strategy may be a useful and practical form of gene therapy against human restenosis after coronary intervention. Because of a potential pathogenetic role of MCP-1 in other treatment-intractable inflammatory disorders, our strategy may have broader clinical applications. From a clinical point of view, potential side effects of our anti-MCP-1 gene therapy merit mention. We assume that blockade of MCP-1 with our strategy may not cause serious local or systemic side effects because 1) mice lacking MCP-1 or CCR2 display no serious health problems, 2) the delivery of plasmid DNA by intramuscular injection is now in clinical stages and is proven to be safe, and 3) we have determined that intramuscular transfer of 7ND gene is nontoxic and safe in nonhuman primates. However, we have not yet investigated whether long-term inhibition of MCP-1 function may affect systemic immunoprotective ability in humans. Future study will require careful observation over a long time to establish the true risk/benefit ratio. 
